3 Big Questions on Our Mind Heading Into BIO 2025

BIO 2025 is nearly here, and it’s happening during an interesting environment for Biotech. The industry is shifting — fast — from how companies are getting funded to how they’re building teams, platforms, and partnerships for long-term success.

Here are three of the biggest questions we’re thinking about as we head into BIO:

Will Biotech Funding Bounce Back?

After a tough couple of years for early-stage funding, all eyes are on venture capital (VC). Will we see a meaningful rebound in the second half of 2025? What areas are VCs feeling most confident about right now?

We’ll be listening closely for signs of optimism (or caution) — especially around how platform and early clinical-stage companies are positioning themselves to attract investment.

Platform Biotech: From Possibility to Focus

Platform biotech companies have a unique challenge: their technology can generate dozens of drug candidates — but resources are always limited.

So how do these companies choose where to focus?

• Do they prioritize rare disease or broad market indications?
• Are their teams and processes ready to transition from discovery to development?
• How are they demonstrating thoughtful execution to potential partners and investors — without spreading themselves too thin?

We’re watching for how these organizations are showing they’re ready to grow.

In-Sourcing vs. Out-Sourcing: What’s Shifting?

One of the most interesting debates happening right now is how companies are thinking about their internal vs. external capabilities.

Is aggressive outsourcing still the norm, or are more organizations building out internal teams?
How are leaders weighing cost savings against strategic value when choosing partners?

We’re excited to hear how different companies are navigating this decision — and how that’s shaping workforce strategies across the industry.

Let’s Connect at BIO 2025

Whether you’re attending sessions or just spending time in the networking halls, we’d love to hear your perspective on these questions, too. If you’re focused on building biotech teams or preparing your organization for its next phase of growth, come find us — or reach out here to set up time to talk.